Aptamer signs agreement to explore Optimer vehicles for targeted delivery of siRNA
LONDON: Aptamer Group plc (AIM: APTA) announced a new agreement with AstraZeneca, a global biopharmaceutical company, to evaluate the Optimer fibrotic liver delivery vehicles for the targeted delivery of siRNA. Following the encouraging results achieved to-date with Aptamer’s fibrotic liver…